Abstract
Human cerebrospinal fluid (CSF) is a sample of choice in the study of brain disorders. This biological fluid circulates in the brain and the spinal cord and contains tissue-specific proteins, indicative of health and disease conditions. Despite its potential as a valid source of biological markers, CSF remains largely understudied as compared to blood, in particular due to its more invasive way of sampling.
Challenges remain when performing proteomic analysis in clinical research studies. State-of-the-art mass spectrometry (MS) enables deep characterization of the human proteome. But some technical limitations are cardinal to be addressed, such as the capacity to routinely analyze large cohorts of samples. Importantly, a trade-off still needs to be made between the proteome coverage depth and the number of measured samples. In this context, we developed a scalable automated proteomic pipeline for the analysis of CSF. Because of its versatility, this workflow can be adapted to accommodate proteome coverage and/or sample throughput. It allows us to prepare and quantitatively analyze hundreds to thousands of CSF samples; it can also allow identification of more than 3000 proteins in a CSF sample when coupled with isoelectric focusing fractionation.
In this chapter, we describe an end-to-end pipeline for the proteomic analysis of CSF. The main steps of the sample preparation comprise spiking of a standard, protein digestion, isobaric labeling, and purification; these are performed in a 96-well plate format enabling automation. Depending on the targeted depth of the CSF proteome, optional analytical steps can be included, such as the removal of abundant proteins and sample pre-fractionation. Liquid chromatography tandem MS as well as data processing and analysis complete the pipeline.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Halbgebauer S, Ockl P, Wirth K, Steinacker P, Otto M (2016) Protein biomarkers in Parkinson’s disease: focus on cerebrospinal fluid markers and synaptic proteins. Mov Disord 31(6):848–860
Lewczuk P, Mroczko B, Fagan A, Kornhuber J (2015) Biomarkers of Alzheimer’s disease and mild cognitive impairment: a current perspective. Adv Med Sci 60(1):76–82
Begcevic I, Brinc D, Drabovich AP, Batruch I, Diamandis EP (2016) Identification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas. Clin Proteomics 13:11
Sancesario GM, Bernardini S (2018) Diagnosis of neurodegenerative dementia: where do we stand, now? Ann Transl Med 6(17):340
Guldbrandsen A, Vethe H, Farag Y, Oveland E, Garberg H, Berle M, Myhr KM, Opsahl JA, Barsnes H, Berven FS (2014) In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). Mol Cell Proteomics 13(11):3152–3163
Zhang Y, Guo Z, Zou L, Yang Y, Zhang L, Ji N, Shao C, Sun W, Wang Y (2015) A comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome. J Proteomics 119:90–99
Macron C, Lane L, Nunez Galindo A, Dayon L (2018) Deep dive on the proteome of human cerebrospinal fluid: a valuable data resource for biomarker discovery and missing protein identification. J Proteome Res 17(12):4113–4126
Paik YK, Jeong SK, Omenn GS, Uhlen M, Hanash S, Cho SY, Lee HJ, Na K, Choi EY, Yan F, Zhang F, Zhang Y, Snyder M, Cheng Y, Chen R, Marko-Varga G, Deutsch EW, Kim H, Kwon JY, Aebersold R, Bairoch A, Taylor AD, Kim KY, Lee EY, Hochstrasser D, Legrain P, Hancock WS (2012) The chromosome-centric human proteome project for cataloging proteins encoded in the genome. Nat Biotechnol 30(3):221–223
Macron C, Lane L, Nunez Galindo A, Dayon L (2018) Identification of mssing proteins in normal human cerebrospinal fluid. J Proteome Res 17(12):4315–4319
Portelius E, Brinkmalm G, Pannee J, Zetterberg H, Blennow K, Dahlen R, Brinkmalm A, Gobom J (2017) Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update. Expert Rev Proteomics 14(11):1007–1020
Nunez Galindo A, Kussmann M, Dayon L (2015) Proteomics of cerebrospinal fluid: throughput and robustness using a scalable automated analysis pipeline for biomarker discovery. Anal Chem 87(21):10755–10761
Dayon L, Nunez Galindo A, Corthesy J, Cominetti O, Kussmann M (2014) Comprehensive and scalable highly automated MS-based proteomic workflow for clinical biomarker discovery in human plasma. J Proteome Res 13:3837–3845
Cominetti O, Nunez Galindo A, Corthesy J, Oller Moreno S, Irincheeva I, Valsesia A, Astrup A, Saris WH, Hager J, Kussmann M, Dayon L (2016) Proteomic biomarker discovery in 1000 human plasma samples with mass spectrometry. J Proteome Res 15(2):389–399
Dayon L, Nunez Galindo A, Cominetti O, Corthesy J, Kussmann M (2017) A highly automated shotgun proteomic workflow: clinical scale and robustness for biomarker discovery in blood. Methods Mol Biol 1619:433–449
Lan J, Nunez Galindo A, Doecke J, Fowler C, Martins RN, Rainey-Smith SR, Cominetti O, Dayon L (2018) Systematic evaluation of the use of human plasma and serum for mass-spectrometry-based shotgun proteomics. J Proteome Res 17(4):1426–1435
Maienschein-Cline M, Lei Z, Gardeux V, Abbasi T, Machado RF, Gordeuk V, Desai AA, Saraf S, Bahroos N, Lussier Y (2014) ARTS: automated randomization of multiple traits for study design. Bioinformatics 30(11):1637–1639
Yan L, Ma C, Wang D, Hu Q, Qin M, Conroy JM, Sucheston LE, Ambrosone CB, Johnson CS, Wang J, Liu S (2012) OSAT: a tool for sample-to-batch allocations in genomics experiments. BMC Genomics 13:689
Dayon L, Nunez Galindo A, Wojcik J, Cominetti O, Corthesy J, Oikonomidi A, Henry H, Kussmann M, Migliavacca E, Severin I, Bowman GL, Popp J (2018) Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimers Res Ther 10(1):66
Dayon L, Wojcik J, Nunez Galindo A, Corthesy J, Cominetti O, Oikonomidi A, Henry H, Migliavacca E, Bowman GL, Popp J (2017) Plasma proteomic profiles of cerebrospinal fluid-defined Alzheimer’s disease pathology in older adults. J Alzheimers Dis 60(4):1641–1652
Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Walden A, Wan J, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Ponten F (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4(12):1920–1932
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Macron, C., Núñez Galindo, A., Cominetti, O., Dayon, L. (2019). A Versatile Workflow for Cerebrospinal Fluid Proteomic Analysis with Mass Spectrometry: A Matter of Choice between Deep Coverage and Sample Throughput. In: Santamaría, E., Fernández-Irigoyen, J. (eds) Cerebrospinal Fluid (CSF) Proteomics. Methods in Molecular Biology, vol 2044. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9706-0_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9706-0_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9705-3
Online ISBN: 978-1-4939-9706-0
eBook Packages: Springer Protocols